ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM)
Lassman, Andrew, Pugh, Stephanie, Wang, Tony, Aldape, Kenneth, Gan, Hui, Preusser, Matthias, Vogelbaum, Michael, Sulman, Erik, Won, Minhee, Zhang, Peixin, Moazami, Golnaz, Macsai, Marian, Gilbert, MarVolume:
21
Journal:
Neuro-Oncology
DOI:
10.1093/neuonc/noz175.064
Date:
November, 2019
Fichier:
PDF, 90 KB
2019
File converter
Plus de résultats de recherche
More benefits 
